Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 1:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 92 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Refractory Seizures Clear all
Enrolling by invitation Not applicable Interventional

Electrochemical and Electrophysiological Study

NCT05273970
View directory record Official record
Conditions
Cognition, Medically Intractable Epilepsy
Interventions
Behavioral testing under intracranial monitoring
Other
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 20, 2026, 1:03 AM EDT
Completed Phase 3 Interventional Results available

Retigabine Efficacy and Safety Trial for Partial Onset Refractory Seizures in Epilepsy

NCT00235755
View directory record Official record
Conditions
Seizures
Interventions
Retigabine, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
539 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
2
States / cities
Bethesda, Maryland • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 21, 2017 · Synced Oct 20, 2026, 1:03 AM EDT
Terminated Phase 4 Interventional

Efficacy and Safety of Perampanel in the Treatment of Refractory Status Epilepticus

NCT05684978
View directory record Official record
Conditions
Refractory Status Epilepticus
Interventions
Perampanel
Drug
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 100 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 20, 2026, 1:03 AM EDT
Completed Phase 2 Interventional Results available

4-Year Open-Label Extension Phase of the Parallel-Group Study of E2007 in Patients With Refractory Partial Seizures

NCT00368472
View directory record Official record
Conditions
Epilepsy
Interventions
Perampanel
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
12
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2015 · Synced Oct 20, 2026, 1:03 AM EDT
Terminated Not applicable Interventional

Feasibility Study: tDCS for Treatment of Refractory Status Epilepticus

NCT05934903
View directory record Official record
Conditions
Status Epilepticus, Refractory Status Epilepticus
Interventions
Transcranial Direct Current Stimulation
Device
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 4, 2025 · Synced Oct 20, 2026, 1:03 AM EDT
Withdrawn Phase 3 Interventional

Safety Study of Rufinamide Given as an add-on Therapy to Treat Patients With Seizures

NCT04558580
View directory record Official record
Conditions
Refractory Partial Seizures
Interventions
Rufinamide
Drug
Lead sponsor
University of South Alabama
Other
Eligibility
12 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Mobile, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 22, 2020 · Synced Oct 20, 2026, 1:03 AM EDT
Terminated Phase 3 Interventional Results available

Treatment of Refractory Status Epilepticus

NCT00265616
View directory record Official record
Conditions
Status Epilepticus
Interventions
propofol, thiopental/pentobarbital
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
16 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 9, 2013 · Synced Oct 20, 2026, 1:03 AM EDT
Withdrawn Not applicable Interventional

Treatment Resistant Epilepsy and N-Acetyl Cysteine

NCT02054949
View directory record Official record
Conditions
Autistic Disorder, Seizures, Irritability
Interventions
N-Acetyl Cysteine (NAC)
Drug
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
6 Years to 21 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 9, 2015 · Synced Oct 20, 2026, 1:03 AM EDT
Completed Phase 3 Interventional Results available

To Evaluate The Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures

NCT00699582
View directory record Official record
Conditions
Refractory Partial Seizures
Interventions
E2007 (perampanel), Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
12 Years and older
Enrollment
389 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
32
States / cities
Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2014 · Synced Oct 20, 2026, 1:03 AM EDT
Enrolling by invitation Not applicable Interventional

Low-Intensity Focused Ultrasound Neuromodulation for Epilepsy

NCT07353918
View directory record Official record
Conditions
Epilepsy (Treatment Refractory), Epilepsy Comorbidities
Interventions
Low-intensity Focused Ultrasound, Sham
Device
Lead sponsor
Carilion Clinic
Other
Eligibility
18 Years to 85 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Roanoke, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Oct 20, 2026, 1:03 AM EDT
Terminated Phase 3 Interventional Results available

Open-Label Extension Study of Rufinamide Given as Adjunctive Therapy in Patients With Refractory Partial Seizures

NCT00448539
View directory record Official record
Conditions
Refractory Partial Onset Seizures
Interventions
Rufinamide
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
12 Years to 80 Years
Enrollment
286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
27
States / cities
Mobile, Alabama • Little Rock, Arkansas • Bradenton, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2019 · Synced Oct 20, 2026, 1:03 AM EDT
Completed Phase 2 Interventional Results available

Study of Adjunctive Ganaxolone Treatment in Female Children With Protocadherin 19 (PCDH19)-Related Epilepsy (Violet Study)

NCT03865732
View directory record Official record
Conditions
PCDH19-Related Epilepsy
Interventions
Ganaxolone, Placebo
Drug
Lead sponsor
Marinus Pharmaceuticals
Industry
Eligibility
1 Year to 17 Years · Female only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
6
States / cities
Little Rock, Arkansas • Los Angeles, California • San Francisco, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2023 · Synced Oct 20, 2026, 1:03 AM EDT
Completed Phase 4 Interventional Results available

A Study of the Structure and Function of the Retina in Adult Patients With Refractory Complex Partial Seizures Treated With Vigabatrin (Sabril®)

NCT01278173
View directory record Official record
Conditions
Adult Refractory Complex Partial Seizures
Interventions
Sabril
Drug
Lead sponsor
Lundbeck LLC
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
22
States / cities
San Francisco, California • New Haven, Connecticut • Dover, Delaware + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2016 · Synced Oct 20, 2026, 1:03 AM EDT
Completed Phase 3 Interventional Results available

Retigabine (Adjunctive Therapy) Efficacy and Safety Study for Partial Onset Refractory Seizures in Epilepsy

NCT00232596
View directory record Official record
Conditions
Seizures
Interventions
Retigabine, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
32
States / cities
Birmingham, Alabama • Huntsville, Alabama • Northport, Alabama + 26 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2016 · Synced Oct 20, 2026, 1:03 AM EDT
Completed No phase listed Observational

Transcranial Magnetic Stimulation for the Treatment of Poorly Controlled Partial Epilepsy

NCT00001666
View directory record Official record
Conditions
Partial Epilepsy, Seizures
Interventions
Cadwell High-Speed Magnetoelectric Stimulator, Magpro High-Speed Magnetoelectric Stimulator
Device
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 20, 2026, 1:03 AM EDT
Completed Phase 1 Interventional

Use of the Atkins Diet for Children With Intractable Epilepsy: A Comparison of Daily Carbohydrate Limits

NCT00181090
View directory record Official record
Conditions
Epilepsy
Interventions
Modified Atkins diet
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
3 Years to 18 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 27, 2009 · Synced Oct 20, 2026, 1:03 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

P-glycoprotein Inhibition as Adjunct Treatment for Medically Refractory Epilepsy.

NCT00524134
View directory record Official record
Conditions
Epilepsy
Interventions
Carvedilol-CR
Drug
Lead sponsor
Columbia University
Other
Eligibility
10 Years to 75 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 23, 2016 · Synced Oct 20, 2026, 1:03 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Safety and Effectiveness of USL255 in Patients With Refractory Partial-onset Seizures

NCT01142193
View directory record Official record
Conditions
Epilepsy
Interventions
USL255, Placebo
Drug
Lead sponsor
Upsher-Smith Laboratories
Industry
Eligibility
18 Years to 75 Years
Enrollment
249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
19
States / cities
Phoenix, Arizona • Ventura, California • Gainesville, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated May 22, 2014 · Synced Oct 20, 2026, 1:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Relative Bioavailability of a New Formulation of NPT 2042 Soft-Gelatin Capsules Compared to the Original Formulation of NPT 2042

NCT07222878
View directory record Official record
Conditions
Epilepsy, Alzheimer Disease, Epilepsy Intractable
Interventions
NPT 2042 (Reference formula/Formulation 1), NPT 2042 (Test formula/Formulation 2)
Drug
Lead sponsor
NeuroPro Therapeutics, Inc.
Industry
Eligibility
19 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 20, 2026, 1:03 AM EDT
Withdrawn Phase 3 Interventional

Levetiracetam, Lacosamide and Ketamine as Adjunctive Treatment of Refractory Status Epilepticus

NCT02726867
View directory record Official record
Conditions
Epilepsy, Status Epilepticus
Interventions
levetiracetam, lacosamide, Ketamine, Phenobarbital
Drug
Lead sponsor
Mid-Atlantic Epilepsy and Sleep Center, LLC
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 29, 2017 · Synced Oct 20, 2026, 1:03 AM EDT
Completed Phase 2 Interventional

Study Evaluating the Safety and Efficacy of RAP-219 in Adult Participants With Refractory Focal Epilepsy

NCT06377930
View directory record Official record
Conditions
Focal Onset Seizures
Interventions
RAP-219
Drug
Lead sponsor
Rapport Therapeutics Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
12
States / cities
New Haven, Connecticut • Boise, Idaho • Indianapolis, Indiana + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 20, 2026, 1:03 AM EDT
Not yet recruiting Not applicable Interventional

High-Intensity Focused Ultrasonic Ablation of the Centromedian Thalamic Nucleus for Treatment of Medically Refractory Generalized Epilepsy in Patients Ages 18 Years to 89 Years

NCT07803692
View directory record Official record
Conditions
Idiopathic Generalized Epilepsy
Interventions
Intervention 1, Intervention 2
Device
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 89 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2031
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 20, 2026, 1:03 AM EDT
Enrolling by invitation Phase 2 Interventional

Long-term Safety and Tolerability of BHV-7000

NCT06443463
View directory record Official record
Conditions
Focal Epilepsy
Interventions
BHV-7000
Drug
Lead sponsor
Biohaven Therapeutics Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
660 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
115
States / cities
Birmingham, Alabama • Peoria, Arizona • Phoenix, Arizona + 92 more
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 20, 2026, 1:03 AM EDT
Completed Phase 3 Interventional Results available

Open-label Extension Study to Evaluate the Safety of USL255 in Patients With Refractory Partial-onset Seizures

NCT01191086
View directory record Official record
Conditions
Epilepsy
Interventions
USL255
Drug
Lead sponsor
Upsher-Smith Laboratories
Industry
Eligibility
18 Years to 75 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
16
States / cities
Phoenix, Arizona • Ventura, California • Gainsville, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2015 · Synced Oct 20, 2026, 1:03 AM EDT